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Duloxetine versus Routine Care in the Long-Term
Management of Diabetic Peripheral Neuropathic Pain
JOEL RASKIN, M.D., F.R.C.P.C.,1 TIMOTHY R. SMITH, M.D., R.Ph., F.A.C.P.,2
KAR WONG, Ph.D., YILI LU PRITCHETT, Ph.D.,3 DEBORAH N. D’SOUZA, Ph.D., M.B.A.,3
SMRITI IYENGAR, Ph.D.,3 and J.F. WERNICKE, Ph.D., M.D.3
ABSTRACT
Introduction: Duloxetine hydrochloride is a dual reuptake inhibitor of both serotonin and
norepinephrine. In the present open-label study, the safety of duloxetine at a fixed-dose of
60 mg twice daily (BID) for up to 52 weeks was evaluated and compared to routine care in
the therapy of patients diagnosed with diabetic peripheral neuropathic pain (DPNP).
Methods: Patients who completed a 13-week, double-blind, duloxetine and placebo acute
therapy period were rerandomly assigned in a 2:1 ratio to therapy with duloxetine 60 mg BID
(N  161) or routine care (N  76) for an additional 52 weeks. Routine care consisted primar-
ily of gabapentin, amitriptyline, and venlafaxine. The study included male or female outpa-
tients 18 years of age or older with a diagnosis of DPNP caused by type 1 or type 2 diabetes.
Results: A higher percentage of routine care-treated patients experienced 1 or more serious
adverse events. No statistically significant therapy-group difference was observed in the over-
all incidence of treatment-emergent adverse events (TEAEs). The TEAEs reported by 10% or
more of duloxetine 60 mg BID-treated patients were nausea, and by the routine care-treated
patients were peripheral edema, pain in the extremity, somnolence, and dizziness. Duloxe-
tine did not appear to adversely affect glycemic control, lipid profiles, nerve function, or the
course of DPNP. There were no statistically significant therapy-group differences observed
in the 36-item Short-Form Health Survey subscales or in the EuroQol 5-Dimension Ques-
tionnaire.
Conclusions: In this study, duloxetine was safe and well tolerated compared to routine care
in the long-term management of patients with DPNP.
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INTRODUCTION
DIABETES MELLITUS is a common disease, af-fecting approximately 6.3% (18.2 million) of
the population in the United States.1 Approxi-
mately 30%–60% of patients with diabetes de-
velop long-term complications of peripheral neu-
ropathy, and up to 10%–20% of these patients
experience pain.2–4 This pain is often described as
an “aching, burning, stabbing, or tingling” sen-
sation3 and is characterized by hyperalgesia,
paresthesia, and allodynia.5–7
The neurotransmitters serotonin (5-HT) and
norepinephrine (NE) have been implicated in the
modulation of endogenous analgesic mecha-
nisms via the descending inhibitory pain path-
1Lilly Research Laboratories, Toronto, Canada.
2Mercy Health Research, Ryan Headache Center, Washington University School of Medicine, St. Louis, Missouri.
3Lilly Research Laboratories, Indianapolis, Indiana.
ways in the brain and spinal cord.8,9 In pathologic
pain states, these endogenous pain inhibitory
mechanisms may be dysfunctional. This may con-
tribute to the central sensitization and hyperex-
citability of the spinal and supraspinal pain trans-
mitting pathways that may manifest as persistent
pain.10
Tricyclic antidepressants (TCAs) with reuptake
inhibitory activity for both 5-HT and NE have been
widely used in the management of DPNP.11,12 Hy-
pothetically, dual reuptake inhibitors unburdened
by the undesirable pharmacologic effects of TCAs
should be better tolerated and more effective in
managing diabetic peripheral neuropathic pain
(DPNP). This hypothesis is supported by the find-
ing that amitriptyline (5-HT and NE reuptake in-
hibitor) is superior to desipramine (NE reuptake
inhibitor), which is superior to fluvoxamine (5-HT
reuptake inhibitor) in providing pain relief.13 In a
crossover study comparing 4-week treatment pe-
riods, venlafaxine and imipramine were found 
to be superior to placebo in relieving DPNP.14
Other drugs reported to manage DPNP are “anti-
convulsants,”15,16 selective serotonin reuptake in-
hibitors,17 controlled-release oxycodone,18,19 and
the synthetic cannabinoid CT-3.20
Duloxetine hydrochloride (Cymbalta®, Eli Lilly
and Company, Indianapolis, IN) is a selective 5-
HT and NE reuptake inhibitor that is relatively
balanced in its affinity for both 5-HT and NE 
reuptake inhibition.21 Because central sensitiza-
tion is believed to be involved in the development
and maintenance of chronic neuropathic pain, in-
cluding DPNP, patients with DPNP may benefit
from duloxetine therapy. Duloxetine (40 to 120 mg
daily) has been shown to be safe and effective in
the treatment of major depression.22–26 Duloxetine
is the first Food and Drug Administration (FDA)-
approved prescription drug for the management
of DPNP. In a randomized, controlled, 12-week
trial comparing duloxetine 60 mg once daily (QD)
and duloxetine 60 mg twice daily (BID) or dulox-
etine 20 mg QD with placebo in 457 patients with
DPNP and without depression, duloxetine was
found to be effective and safe for DPNP manage-
ment.27 Based on this evidence, two more inde-
pendent 12-week acute therapy studies were con-
ducted, and these studies confirmed the safety and
efficacy of duloxetine 60 mg QD and 60 mg BID
in the management of patients with DPNP.28,29
The study presented here was conducted in order
to evaluate the safety, as well as the impact of ther-
apy on patient-reported health outcomes with up
to 65 weeks exposure with duloxetine 60 mg BID
or routine care. It is a one-year extension of an
acute study, the results of which were previously
reported.28
Study objectives
The objectives of this study were to evaluate
the safety of duloxetine 60 mg BID over a 52-
week open-label extension period, to evaluate the
safety of duloxetine 60 mg BID for up to 65-week
exposure with regard to the progression of dia-
betic complications, and to assess the impact of
treatment with duloxetine 60 mg BID and routine
care on patient-reported health outcomes.
METHODS
Study design and treatments
This study was a 52-week, randomized, open-
label, extension trial comparing duloxetine and
routine care in patients with DPNP. This multi-
center study included 26 principal investigators,
and was conducted at 27 investigative sites in the
United States and Puerto Rico. The acute therapy
phase of this study was 12 weeks in duration,
with an additional 1-week drug-tapering phase.
The extension therapy phase was 52 weeks, mak-
ing the total duration of the study 65 weeks. Only
those patients who completed the acute period of
the study, independent of treatment assignment,
were allowed to continue into the extension phase
of the study. Patients were rerandomized (2:1) to
either duloxetine therapy or routine care. Patients
rerandomized to the duloxetine therapy group
began on 60 mg QD for 3 days and then received
60 mg BID until 1 week prior to week 52 of the
extension phase of the study, at which time the
patient was instructed to reduce the dose of du-
loxetine to 60 mg QD. Patients could reduce their
dose of duloxetine to 60 mg QD if they could not
tolerate a dose of 60 mg BID.
Duloxetine was provided as 30-mg capsules
and patients were instructed to take 4 capsules
orally each day. Patients were seen after 1 week
(week 14) of treatment with either duloxetine or
routine care. They were then seen again at weeks
17, 21, 25, 33, 41, 49, 57, and 65 of treatment. Com-
pliance was defined as taking between 80% and
120% of the study medication prescribed for each
interval.
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The routine care group was treated with ther-
apies that the investigator and the patient be-
lieved permitted the optimal benefit to the pa-
tient. The duloxetine-treated patients received
most therapies, including nonmedicinal therapy
offered to the routine care group, with the ex-
ception of antidepressants, anticonvulsants, and
antipsychotics. During this period, patients in
both treatment groups were permitted to sup-
plement their analgesia with acetaminophen,
nonsteroidal anti-inflammatory drugs (NSAIDs),
or opioid analgesics.
The ethical review boards provided approval
of the study protocol in accordance with the prin-
ciples of the Declaration of Helsinki, and all pa-
tients provided written informed consent after
the study was explained and prior to the perfor-
mance of any protocol procedures and adminis-
tration of the study drug.
Entry criteria
As detailed in Raskin et al.,29 patients were el-
igible for the study if they were 18 years or older,
and presented with pain due to bilateral periph-
eral neuropathy caused by type 1 or type 2 dia-
betes mellitus. The pain had to begin in the feet
and with relatively symmetrical onset. The daily
pain should have been present for at least 6
months; neuropathy was confirmed by a score of
at least 3 on the Michigan Neuropathy Screening
Instrument (MNSI).30 Patients had to have a
mean score of 4 or more when assessed by 24-
hour average pain severity on an 11-point Likert
scale, stable glycemic control, and a glycosylated
hemoglobin (HbA1c) of 12% or more. Some of the
reasons for patient exclusion were serious or un-
stable illness, current (1 year) Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition
Axis I diagnosis of major depressive disorder, his-
torical exposure to drugs known to cause neu-
ropathy, a positive urine drug screen for sub-
stances of abuse, or excluded medication.
Safety assessments
Safety of duloxetine over the 52-week open-la-
bel extension period was measured by discontin-
uation rates, treatment-emergent adverse events
(TEAEs), laboratory assessments, including lipid
profile and glycosylated hemoglobin (HbA1c),
weight, and electrocardiograms (ECGs). A TEAE
was defined as an event that first occurred or
worsened after random assignment. Vital signs
including heart rate and blood pressure were
recorded. A patient considered to have sustained
elevation in blood pressure after randomization
met the following criteria: sitting diastolic blood
pressure 85 mm Hg or more and increase from
baseline of 10 mm Hg for 3 consecutive visits, or
sitting systolic blood pressure 130 mm Hg or
more and increase from baseline of 10 mm Hg for
3 consecutive visits.
The safety of duloxetine for up to 65 weeks was
also evaluated with regard to the progression of
diabetic complications, as measured by the MNSI
(neuropathy progression), electrophysiology as-
sessments (measures included ulnar F-wave, ul-
nar distal sensory latency, peroneal F-wave, 
peroneal compound muscle action potential
[CMAP]), microalbumin/creatinine ratio (ne-
phropathy progression), and an ophthalmologic
examination (measures for retinopathy progres-
sion included worsening of visual acuity, proce-
dures required, reasons for photocoagulation,
and reasons for vitrectomy). Changes from base-
line to endpoint were assessed where baseline
refers to values collected prior to the acute ther-
apy phase, and endpoint refers to values collected
at week 65 of treatment or at an early discontin-
uation visit between week 41 and week 65 of
treatment.
All data were collected at week 65 of treatment
or at an early discontinuation visit between
weeks 14 and 65 of treatment. In addition, data
on vital signs, adverse events, and concomitant
medications were collected at each visit starting
from week 14 until week 65 of treatment, ECG
data were collected at weeks 14 and 49 of treat-
ment, and samples for HbA1c and clinical chem-
istry profiles were collected at week 49 of treat-
ment.
Health outcome measures
The impact of therapy with duloxetine 60 mg
BID and routine care on patient-reported health
outcomes was measured by the 36-item Short
Form Health Survey (SF-36)31 and the EuroQol
Questionnaire—5-Dimension (EQ-5D).32 The SF-
36 was completed by the patient to measure how
the patient perceives general health status. The
EQ-5D was completed by the patient to measure
how severe the patient perceived general health.
In the SF-36 and EQ-5D index, baseline refers
to values collected at the end of the acute ther-
apy phase, and the endpoint refers to values col-
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lected at week 65 of treatment or at an early dis-
continuation visit between week 14 and week 65
of treatment.
Statistical analysis
All analyses were conducted on an intent-to-
treat basis. Therapy effects were evaluated based
on a two-sided significance level of 0.05, and in-
teraction effects at 0.10. No adjustments for mul-
tiple comparisons were made. Application soft-
ware (SAS, Version 8.0 SAS, Inc., Cary, NC) was
used to perform all statistical analyses.
For categorical data, therapy group compar-
isons were made using Fisher’s exact test. These
include reasons for patient disposition, patient
characteristics (e.g., gender, origin, types of dia-
betic mellitus), concomitant medication use, and
safety endpoints (e.g., adverse events). For con-
tinuous data, therapy group comparisons were
made using a type III sum-of-squares analysis of
variance (ANOVA) model, with the terms of ther-
apy and investigator. These include patient char-
acteristics at baseline (e.g., age, height, and
weight, duration of diabetes, duration of diabetic
neuropathy, and Michigan Neuropathy Screen-
ing Score), duration of exposure, change from
baseline for vital signs, ECG parameters, and
ranked laboratory assessments.
Assessments of change from baseline for the
MNSI, electrophysiology measures, and ranked
microalbumin/creatinine ratio were made using
a type II sum-of-squares ANOVA model with
terms of investigator, acute therapy (duloxetine or
placebo), extension therapy, and acute therapy by
extension therapy. Testing the significance of the
therapy factor in the extension phase was of pri-
mary interest. Ophthalmologic exams that sum-
marized worsening in visual acuity and the types
of procedures required during the study were an-
alyzed using the Cochran-Mantel-Haenszel gen-
eral association test, controlling for acute therapy.
For the EQ-5D index, and each of the SF-36 do-
mains, including physical and mental component
summaries, therapy-group differences in the
mean change from baseline to endpoint were
evaluated using a type III sum-of-squares analy-
sis of covariance (ANCOVA) model with terms
of baseline, investigator, and therapy in the
model. In addition, investigator-by-therapy in-
teraction was assessed by adding this term to the
above model with a type II estimate approach.
RESULTS
Patient disposition, demographics, and 
disease characteristics
Two hundred thirty-seven patients who com-
pleted the acute therapy period were rerandomly
assigned to therapy with either duloxetine 60 mg
BID (N  161) or routine care (N  76). There
were no statistically significant therapy-group
differences observed in any of the patient demo-
graphics or disease characteristics (Table 1). The
majority of the patients were male (61.2%) and
Caucasian (78.5%). The mean patient age was 60
years and the mean MNSI score was 5.7. The
mean duration of diabetes in all patients was 9.9
years with type 2 diabetes being the most preva-
lent (90%).
A total of 179 (75.5%) patients completed the
extension phase of the study (116 [72%] duloxe-
tine-treated and 63 [82.9%] routine care-treated
group). The reasons for study discontinuation are
summarized in Table 2. There were no statisti-
cally significant differences observed between
routine care and duloxetine therapy for any of the
reasons for discontinuation.
Concomitant medications
Table 3 summarizes concomitant medications
used by at least 5% of patients. A statistically sig-
nificant therapy-group difference was observed
with regard to concomitant use of Neurontin
(gabapentin), Lantus (insulin glargine injection),
Amaryl (glimerpiride), and Lasix (furosemide).
Neurontin (gabapentin) use was allowed only 
in the routine care-treated group. A significantly
smaller percentage of duloxetine-treated patients
reported taking these medications. The most fre-
quently reported concomitant medications used
by all patients were glucophage, aspirin, Avan-
dia (rosiglitazone), Neurontin (gabapentin—for
routine care-treated group only), Lipitor (ator-
vastatin), Tylenol (acetaminophen), and Actos
(pioglitazone).
Table 4 presents medications used by pa-
tients in the routine care group for DPNP. The
most commonly used pain medications for rou-
tine care-treated patients included Neurontin
(gabapentin), Elavil (amitriptyline), Effexor-XR




Extent of exposure. The mean duration of expo-
sure (days) was significantly longer (p  0.032)
for routine care-treated patients (mean days
[standard deviation [SD]: 336.4 [70.8]) compared
to duloxetine-treated patients (mean days [SD]:
304.2 [116.1]). The median duration was similar
for both groups and was approximately 1 year.
The total patient–years of exposure was 134.1 for
the duloxetine-treated group and 70.0 for the rou-
tine care-treated group.
Deaths. During the study, 4 deaths (2 duloxe-
tine-treated patients and 2 routine care-treated
patients) occurred, which were considered by the
investigators to be unrelated to the study drug or
the protocol procedures. The cause of death in the
2 duloxetine-treated patients was myocardial in-
farction and acute myocardial infarction, and in
the 2 routine care-treated patients was myocar-
dial infarction and pulmonary embolism. The
mortality rate per 100,000 patient–years was
1491.5 for the duloxetine-treated group, 2857.6 for
the routine care-treated group, and 1960.0 for the
combined population.
Serious adverse events. During the study, a sig-
nificantly higher percentage of routine care-
treated patients experienced 1 or more serious ad-
verse events (SAE) (28.9% routine care-treated
versus 16.8% duloxetine-treated; p  0.039). A
significant therapy group difference was also ob-
served in congestive heart failure, with a higher
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TABLE 1. DEMOGRAPHICS AND BASELINE ASSESSMENTS
Duloxetine Routine care
Variable (N  161) (N  76)
Mean age, years, (SD) 59.7 (10.7) 60.6 (10.3)
Gender
Female, n (%) 62 (38.5) 30 (39.5)
Male, n (%) 99 (61.5) 46 (60.5)
Race (origin)
Caucasian, n (%) 128 (79.5) 58 (76.3)
Hispanic, n (%) 26 (16.1) 14 (18.4)
African, n (%) 4 (2.5) 2 (2.6)
Western Asian, n (%) 1 (0.6) 0 (0.0)
Other, n (%) 2 (1.2) 2 (2.6)
Mean weight, kg (SD) 101 (24) 105 (25)
Type of Diabetes Mellitus
Type 1, n (%) 15 (9.3) 8 (10.5)
Type 2, n (%) 146 (90.7) 68 (89.5)
Mean duration of diabetes, years (SD) 10.3 (9.5) 9.3 (9.1)
Mean duration of diabetic neuropathy, years (SD) 3.9 (4.5) 3.1 (2.5)
Mean MNSI (SD) 5.6 (1.5) 5.8 (1.5)
MNSI, Michigan Neuropathy Screening Instrument; SD, standard deviation
TABLE 2. PATIENT DISPOSITION
Duloxetine Routine care
(N  161) (N  76)
% %
Completed 52-week study 72.0 82.9
Discontinued because of:
Adverse event 9.3 2.6
Death 1.2 2.6
Unable to contact patient (lost to follow up) 3.7 3.9
Personal conflict or other patient decision 8.7 2.6
Physician decision 0.6 2.6
Protocol violation 1.2 0.0
Lack of efficacy 3.1 2.6
percentage of routine care-treated patients (5.3%)
experiencing this event versus duloxetine-treated
patients (0.6%).
Discontinuations because of adverse events. A to-
tal of 21 (8.9%) patients discontinued due to any
adverse event (including death): 4 (5.3%) routine
care-treated patients (1.3% occurrence of the fol-
lowing events: myocardial infarction, dementia,
fall, pulmonary embolism), and 17 (10.6%) du-
loxetine-treated patients (0.6% occurrence of the
following events: myocardial infarction, acute
myocardial infarction, agitation, chest pain, coro-
nary artery disease, diabetic ketoacidosis, dizzi-
ness, dyskinesia, frequent bowel movements,
gamma-glutamyltransferase increased, hypercal-
caemia, nausea, Parkinson’s disease, pruritus,
surgery, urinary retention, and vomiting).
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TABLE 3. CONCOMITANT MEDICATIONS USED BY AT LEAST FIVE PERCENT OF PATIENTS
Duloxetine Routine care
(N  161) (N  76)
Drug name n % n %
Glucophage 52 (32.3) 22 (28.9)
Aspirin 41 (25.5) 18 (23.7)
Avandia 29 (18.0) 17 (22.4)
Neurontina 0 (0.0) 44 (57.9)
Lipitor 25 (15.5) 18 (23.7)
Tylenol 29 (18.0) 14 (18.4)
Actos 24 (14.9) 18 (23.7)
Lantusb 18 (11.2) 16 (21.1)
Amarylb 17 (10.6) 16 (21.1)
Zocor 23 (14.3) 8 (10.5)
Glyburide 16 (9.9) 14 (18.4)
Calcium 19 (11.8) 8 (10.5)
Metformin 15 (9.3) 12 (15.8)
Multivitamin 17 (10.6) 10 (13.2)
Hydrochlorothiazide 17 (10.6) 9 (11.8)
Lasixb 12 (7.5) 14 (18.4)
Lisinopril 20 (12.4) 6 (7.9)
Atenolol 20 (12.4) 4 (5.3)
Vitamin E 14 (8.7) 10 (13.2)
Diovan 16 (9.9) 7 (9.2)
Glucovance 14 (8.7) 8 (10.5)
Humalog 12 (7.5) 7 (9.2)
Vitamin C 11 (6.8) 8 (10.5)
Altace 13 (8.1) 5 (6.6)
Glipizide 12 (7.5) 6 (7.9)
Plavix 12 (7.5) 5 (6.6)
Acetaminophen 13 (8.1) 3 (3.9)
Nexium 11 (6.8) 5 (6.6)
Glucotrol 11 (6.8) 4 (5.3)
Insulin 8 (5.0) 7 (9.2)
Toprol XL 11 (6.8) 4 (5.3)
Accupril 6 (3.7) 8 (10.5)
Furosemide 12 (7.5) 2 (2.6)
Synthroid 8 (5.0) 6 (7.9)
Amoxicillin 11 (6.8) 2 (2.6)
Prevacid 9 (5.6) 4 (5.3)
Coumadin 5 (3.1) 7 (9.2)
Flomax 10 (6.2) 2 (2.6)
Folic Acid 8 (5.0) 4 (5.3)
Norvasc 9 (5.6) 3 (3.9)
Pravachol 9 (5.6) 3 (3.9)
Protonix 7 (4.3) 5 (6.6)
Viagra 9 (5.6) 3 (3.9)
Zithromax 9 (5.6) 3 (3.9)
ap  0.001.
bp  0.05.
Treatment-emergent adverse events. Of the pa-
tients randomly assigned in the study, 221
(93.2%) patients reported at least 1 TEAE. There
were no therapy-group differences in the overall
incidence of TEAEs. The TEAEs that occurred
with significant therapy-group differences in-
cluded pain in extremity (15.8% versus 6.2%; 
p  0.029), peripheral edema (15.8% versus 5.0%;
p  0.010), balance disorder (5.3% versus 0.6%;
p  0.038), erythema, feeling abnormal, and lo-
calized infections (3.9% versus 0%; p  0.032). All
of these TEAEs occurred at a higher rate in the
routine care-treated group. No significant ther-
apy-group differences in TEAEs occurred in
which patients in the duloxetine-treated group
experienced the highest percentage of events. 
In duloxetine-treated patients, the only TEAE re-
ported by 10% or more of patients was nausea
(10.6%). In routine care-treated patients, the
TEAEs reported by 10% or more of patients were
peripheral edema and pain in extremity (15.8%),
somnolence (14.5%), and dizziness (13.2%). Most
TEAEs were mild or moderate. There were no
significant differences between therapy groups
in the overall incidence of TEAEs that were clas-
sified as severe. A greater percentage of routine
care-treated patients experienced pain in ex-
tremity, peripheral edema, and dyspnoea as se-
vere and this difference was significant. There
were no significant therapy-group differences
observed in the treatment-emergent abnormal
laboratory values at any time for blood chemistry
and urinalysis.
Analysis of chemistry/urinalysis. Table 5 summa-
rizes mean change in chemistry analytes and uri-
nalysis from baseline to endpoint. There was a
slight, but significant, therapy-group difference
in mean change for aspartate transaminase, chlo-
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TABLE 4. SUMMARY OF MEDICATIONS USED BY
AT LEAST FIVE PERCENT OF PATIENTS IN THE
ROUTINE-CARE GROUP FOR TREATMENT OF
DIABETIC PERIPHERAL NEUROPATHIC PAIN









TABLE 5. MEAN (STANDARD DEVIATION) CHANGE FROM BASELINE TO END POINT IN LABORATORY VALUES
N Duloxetine 60 mg BID N Routine care
Alkaline phosphatase (U/L) 153 4.99 (22.24) 69 2.75 (14.39)
ALT/SGPT (U/L) 152 1.96 (12.40) 69 1.48 (15.51)
AST/SGOT (U/L)a 150 1.96 (10.09) 69 1.41 (12.72)
Bicarbonate, HCO3 (mmol/L) 152 1.41 (3.00) 69 1.41 (2.82)
Total bilirubin (mol/L) 152 0.55 (3.08) 69 1.07 (2.49)
Calcium (mmol/L) 153 0.01 (0.12) 69 0.02 (0.10)
Chloride (mmol/L)a 153 3.14 (3.47) 69 2.28 (3.30)
Cholesterol (mmol/L) 153 0.14 (1.10) 69 0.11 (1.09)
Creatinine phosphokinase (U/L) 152 6.93 (122.16) 69 15.80 (127.23)
Creatinine (mol/L) 153 1.51 (16.04) 69 1.28 (19.52)
GGT (U/L) 153 0.10 (32.57) 69 7.38 (37.85)
Glucose, fasting (mmol/L)a 152 0.30 (4.34) 69 0.82 (4.45)
Inorganic phosphorus (mmol/L) 153 0.01 (0.19) 69 0.02 (0.18)
Potassium (mmol/L) 153 0.02 (0.39) 69 0.05 (0.41)
Sodium (mmol/L) 153 1.16 (3.46) 69 0.65 (2.68)
Total protein (g/L) 153 0.74 (3.52) 69 0.62 (4.13)
UA-PH (U) 134 0.02 (0.79) 60 0.13 (0.87)
UA-Specific gravitya 134 0.00 (0.01) 60 0.00 (0.01)
Urea nitrogen (mmol/L) 153 0.19 (1.88) 69 0.32 (2.65)
Uric acid (mol/L)a 153 8.69 (61.82) 69 19.65 (77.16)
Urine albumin (mg/L) 118 18.55 (300.97) 56 11.64 (262.87)
Urine creatinine (mmol/L) 118 0.60 (6.27) 56 0.91 (7.34)
aTherapy-group difference p  0.05.
BID, twice daily; QD, once daily; ALT/SGPT, alanine transaminase/serum glutamate pyruvate transaminase;
AST/SGOT, aspartate transaminase/serum glutamic oxaloacetic transaminase; GGT, -glutamyl transferase.
ride, fasting glucose, urinalysis (UA) specific
gravity and uric acid analytes. For aspartate
transaminase, fasting glucose, and UA specific
gravity, there was a mean increase in duloxetine-
treated patients and a mean decrease for routine
care-treated patients. For uric acid there was a
mean decrease in duloxetine-treated patients and
a mean increase in routine care-treated patients.
For chloride, there was a mean decrease for both
treatment groups and the mean decrease was
greater for duloxetine-treated patients.
Analysis of HbA1c and lipid profile. In the dulox-
etine therapy group, the only analyte with a slight
but significant mean difference compared to rou-
tine care was mean high-density lipoprotein
(HDL) cholesterol-dextran precip (HDL-DX) (p 
0.001). Both therapy groups experienced a de-
crease, with routine care patients experiencing a
greater decrease (mean change [SD]: 0.13 [0.19])
versus duloxetine-treated patients (mean change
[SD]: 0.02 [0.17]). No significant therapy-group
differences were observed in HbA1c, low-density
lipoprotein (LDL) cholesterol, and triglycerides.
Abnormal liver function tests. There were no 
patients who experienced treatment-emergent 
elevated bilirubin concomitant with treatment-
emergent abnormal liver function tests. Three pa-
tients experienced an elevation in liver enzymes
greater than 3 times the Covance upper limit of
normal. Of these, two patients experienced an el-
evation in liver enzymes that were judged to be
unrelated to the study drug. The third patient had
elevated hepatic labs during the acute phase of
the trial, which began to decline during the drug-
tapering phase of the acute therapy period. When
the patient entered the open-label extension
phase and was rerandomized to routine care, the
patient continued in the trial with no further el-
evations in hepatic analytes.
Diabetic complication assessments.
Neuropathy screening instrument: During the
study, there were no significant therapy-group
differences observed in the mean change in the
MNSI score from baseline to endpoint.
Ophthalmologic examination: There were no sig-
nificant therapy-group differences observed for
any of the ophthalmologic examination mea-
sures. These measures included worsening of vi-
sual acuity (left or right), required procedures
(macular laser surgery, panretinal photocoagula-
tion, vitrectomy), reasons for photocoagulation
(neurovascularization, vitreous hemorrhage, or
other), and reasons for vitrectomy (vitreous hem-
orrhage, traction retinal detachment, or other).
Electrophysiology measure: There were no signif-
icant therapy-group differences observed for any
of the electrophysiology measures for either sub-
set of patients. These measures included ulnar 
F-wave, ulnar distal sensory latency, peroneal 
F-wave, peroneal CMAP from baseline to end
point for a subset of randomly assigned patients
with data from the same limbs and for all ran-
domly assigned patients.
Microalbumin/creatinine ratio: There was a sta-
tistically significant therapy-group difference ob-
served in the change in microalbumin/creatinine
ratio from baseline to endpoint (p  0.027). For
the duloxetine therapy group, there was a mean
increase in microalbumin/creatinine ratio (mean
change [SD]: 0.05 [0.27]) that was not of a mag-
nitude to be considered clinically relevant and pa-
tients continued to be well within normal limits
at end point. Routine care-treated patients expe-
rienced a slight mean decrease (mean change
[SD]: 0.01 [0.13]) from baseline to endpoint in
this ratio.
Vital signs, physical findings, and other observa-
tions related to safety.
Sitting blood pressure: Duloxetine-treated pa-
tients experienced a statistically significant (p 
0.049) but slight mean increase in diastolic blood
pressure (mean change [SD]: 1.39 [10.71]) com-
pared to routine care-treated patients who expe-
rienced a slight mean decrease (mean change
[SD]: 1.76 [11.74]). Duloxetine-treated patients
also experienced a statistically significant (p 
0.010) but slight mean increase in pulse (mean
change [SD]: 1.70 [11.82]) compared to routine
care-treated patients who experienced a slight
mean decrease (mean change [SD]: 2.30 [11.29]).
These changes were not considered clinically rel-
evant. There was no significant therapy-group
difference observed in mean change of systolic
blood pressure or weight.
Sustained elevation in blood pressure: One dulox-
etine-treated patient and no routine care-treated
patients met the definition of sustained elevation
in blood pressure and this difference was not sta-
tistically significant. The patient remained in the
study.
Electrocardiograms: Routine care-treated pa-
tients experienced statistically significant mean
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increases in QT interval (mean change [SD]: 5.08
[24.98]; p  0.05), PR (mean change [SD]: 4.60
[17.62]; p  0.015), and QRS (mean change [SD]:
3.82 [10.07]; p  0.026) compared to duloxetine-
treated patients. Duloxetine-treated patients ex-
perienced slight mean decreases in QT interval
(mean change [SD]: 1.50 [25.26]) and PR (mean
change [SD]: 0.81 [15.13]) and a slight mean in-
crease in QRS (mean change [SD]: 0.97 [8.34]).
These changes were not clinically significant, and
there were no other ECG parameters that were
significantly different between therapy groups.
There were no significant therapy-group differ-
ences observed in potentially clinically significant
Fridericia corrected QT (QTcF) intervals.
Health outcomes
Table 6 summarizes the analysis of mean
change from baseline to endpoint on the SF-36
subscales and the EQ-5D. There were no statisti-
cally significant therapy-group differences ob-
served in the SF-36 subscales or on the EQ-5D.
DISCUSSION
The effectiveness of duloxetine in the manage-
ment of DPNP has been established in three 12-
week (acute therapy phase) double-blinded clin-
ical studies.27–29 In these studies, duloxetine 60
mg QD and 60 mg BID demonstrated significant
improvement compared to placebo on the 24-
hour average pain severity score. In addition, pa-
tients who completed one of the 12-week acute
therapy phase studies were rerandomized to du-
loxetine 60 mg BID or routine care for 52 weeks
of open-label treatment in order to evaluate the
safety of duloxetine over long-term administra-
tion.33 A phase 3, long-term, open-label, parallel
safety study of patients with DPNP was also per-
formed, and the efficacy of duloxetine 60 mg BID
and 120 mg QD was observed for up to 28 weeks
in patients with DPNP via the Brief Pain Inven-
tory (BPI) and the Clinical Global Impressions
(CGI) of Severity scale and both doses of dulox-
etine reduced BPI and CGI-Severity scores.34 All
these studies have provided evidence that du-
loxetine is efficacious, safe, and tolerable in the
management of DPNP.
In the study reported here, duloxetine was
well tolerated and safely administered in pa-
tients with DPNP during the 52-week open-label
extension therapy phase of this study. There
were no significant therapy-group differences
observed in any of the patient demographics or
disease characteristics, indicating that the ther-
apy groups were comparable. No significant
therapy group differences were observed in the
physical or mental component scores or in any
of the SF-36 subscales or in the EQ-5D question-
naire. In a previous 52-week study of duloxetine
in the management of DPNP,33 duloxetine was
significantly better on the bodily pain subscale
DULOXETINE AND DIABETIC PERIPHERAL NEUROPATHIC PAIN 37
TABLE 6. MEAN CHANGE IN HEALTH OUTCOME MEASURES
Duloxetine Routine care Group difference in LS
N  149 N  68 mean change from
LS mean change LS mean change baselinea
(SE) (SE) (95% CI)
Short Form 36 Health Status Survey
Mental Health 4.18 (1.29) 0.03 (1.88) 4.22 (8.47, 0.04)
General Health Perceptionsb 3.58 (1.37) 2.91 (2.00) 0.66 (5.2, 3.87)
Bodily Pain 0.05 (1.78) 3.88 (2.60) 3.83 (2.07, 9.72)
Mental Component Summary 3.26 (0.76) 1.06 (1.11) 2.21 (4.71, 0.30)
Physical Component Summary 1.32 (0.73) 0.56 (1.06) 1.87 (0.53, 4.28)
Vitality 2.54 (1.62) 0.37 (2.37) 2.17 (7.54, 3.2)
Social Functions 5.30 (1.81) 4.29 (2.64) 1.02 (7, 4.97)
Physical Role Limit 1.65 (3.22) 0.12 (4.70) 1.53 (9.14, 12.19)
Emotional Role Limit 5.99 (3.20) 5.12 (4.68) 0.87 (11.47, 9.72)
Physical Functioning 4.03 (1.90) 0.08 (2.77) 4.11 (2.17, 10.39)
Euro Quality of Lifec 0.02 (0.02) 0.05 (0.03) 0.02 (0.04, 0.09)
aDifferences in least square (LS) means  Duloxetine LS Mean  Routine Care LS Mean.
bTherapy-by-investigator interaction: p  0.094.
cTherapy-by-investigator interaction: p  0.010. Both interactions were attributed to outlying data for 3 patients
from a single site. Qualitative inferences were similar when this site was excluded from the analysis.
of the SF-36 Health Status Survey, and duloxe-
tine-treated patients perceived their general
health to be better than routine care-treated pa-
tients as measured by the EQ-5D version of the
Euro Quality of Life instrument.
Routine care-treated patients had a longer
mean duration of exposure compared to duloxe-
tine-treated patients. This may have been because
routine care-treated patients were allowed to
switch therapies without discontinuing from the
study, whereas patients in the duloxetine therapy
group could not be prescribed certain other treat-
ments. There were no significant therapy-group
differences observed in the overall incidence of
TEAEs. Most TEAEs were mild or moderate in
severity, and the TEAE reported by 10% or more
of duloxetine-treated patients was nausea
whereas in routine care-treated patients was pe-
ripheral edema, pain in extremity, somnolence,
and dizziness. These findings are consistent with
the known side effect profiles of duloxetine and
gabapentin, the most commonly used drug in the
routine care-treated group. Nausea was also the
most frequently reported TEAE in the acute ther-
apy phase studies, although nausea tended to 
appear early in treatment and subside quickly.
Hypertension was reported as a TEAE in 3.1%
duloxetine- and 2.6% routine care-treated pa-
tients. A significantly higher percentage of rou-
tine care-treated patients experienced 1 or more
SAE with the single event congestive heart fail-
ure. Two routine care-treated patients reported
hypertension as a SAE. There were no significant
therapy-group differences observed in the over-
all incidence of discontinuation due to adverse
events or for any single event.
The reported death rate of 1960.0 (per 100,000
patient–years) is about twice as high as the age
adjusted death rate of 853.3 for all causes between
2000 and 2002.35 The risk for death among people
with diabetes is about two times that of people
without diabetes.36 Thus, the observed death rate
in this study is what would be expected of a pop-
ulation of patients with diabetes, and may actu-
ally be lower than expected if one considers that
disease in these patients is more likely to be more
advanced than in the overall diabetic population.
The observation that the death rate in the routine
care-treated group was about twice as high as in
the duloxetine-treated group is probably an arti-
fact related to the low number of events.
Although duloxetine-treated patients experi-
enced significant mean changes in a few chem-
istry analytes, these were not associated with 
clinical findings and these changes were of in-
sufficient magnitude to have clinical relevance or
represent systemic drug toxicity. Transaminase
increases were not associated with increases in
bilirubin. Duloxetine did not appear to adversely
affect glycemic control or lipid profiles. The use
of duloxetine appears to be associated with a
small increase in fasting glucose in this study,
similar to that seen in an earlier study.34 None of
these changes in analyte concentrations were of
sufficient magnitude to have clinical relevance.
Overall diabetes control does not appear to be af-
fected, as evidenced by the lack of any meaning-
ful changes in HbA1c.
Duloxetine-treated patients experienced a
slight, but significant mean increase in diastolic
blood pressure and pulse compared with routine
care-treated patients. Neither of these effects was
considered clinically relevant. No significant
therapy-group differences were observed in sus-
tained elevation in blood pressure. The observed
increase in pulse rate for the duloxetine-treated
patients could be expected due to elevations in
NE tone.37 These results are supportive of earlier
clinical trials with duloxetine22–25,27–29 and sug-
gest that duloxetine has a safe cardiovascular pro-
file. Routine care-treated patients experienced
significantly higher mean changes in QT, PR, and
QRS intervals compared with duloxetine-treated
patients. No other ECG parameters were signifi-
cantly different between therapy groups, and no
significant therapy-group differences were ob-
served in potentially clinically significant QTcF
intervals. The lack of significant cardiovascular
changes due to duloxetine therapy in these pa-
tients suggests that patients with diabetes melli-
tus do not require more intensive assessment of
their cardiovascular status when treated with du-
loxetine, than they require for their underlying
diabetes. There were no significant therapy-
group differences observed in the MNSI, oph-
thalmologic, and electrophysiologic measures.
The diabetic complications assessments demon-
strated that duloxetine does not appear to ad-
versely affect nerve function or the course of
DPNP, nor does it change the progression of ret-
inopathy.
Although caution must be used when inter-
preting results in an open-label study, the results
of this trial corroborate previous studies that du-
loxetine is safe and well tolerated in the man-
agement of patients with DPNP. In the previously
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reported 52-week study comparing duloxetine 60
mg BID to routine care in the management of
DPNP, duloxetine performed as well as routine
care on most measures of safety, and the dulox-
etine-treated group had significantly higher
scores on the SF-36 bodily pain subscale and on
the EQ-5D.33 In the earlier study, there were no
adverse events that were reported significantly
more frequently in duloxetine-treated patients
compared with routine care-treated patients. The
study reported here provides additional evidence
that duloxetine is safe for long-term therapy of
patients at least 18 years old diagnosed with
DPNP, and the overall safety profile reported
here appears to be similar to that observed in ma-
jor depressive disorder patients22–25,38 as well as
in that observed in other double-blind placebo-
controlled studies of duloxetine in patients with
DPNP.27,28
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